Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • ShortsalgSe hvilke børsnoterede selskaber der har offentliggjorte korte positioner
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Transskriptioner

Læs transskriptioner af webcasts og audiocasts

Transskriptioner

Læs transskriptioner af webcasts og audiocasts

Alle regioner
Danmark
Sverige
Finland
Norge
Seneste
Populært
Fulgt

Biotage, Audiocast, Q1'25

Af Inderes23.4.2025, 07.00
Biotage

Ansvarsfraskrivelse: Dette er en maskin­genereret transskription og kan indeholde unøjagtigheder.

Frederic Vanderhaegen
00:00 - 03:05

Thank you. Good morning, everyone. Welcome to our Q1 report. Thank you for your flexibility today and for accommodating our recent time changes. Today's call is about the Q1 release. We will not comment on the recent announcements made by KKR. We would encourage anyone who has a question to reach out to Torben Jorgensen, who is our chairman of a subcommittee. That will address your questions going forward. Let me talk about our Q1 results. As expected, our Q1 revenue was softer than the prior year, primarily due to the volatility within our bioprocessing, which we had previously commented upon. Our relatively large exposure to the Plasmid preparation business has impacted our overall performance. However, we did see growth in our plasmid preparation revenue and bioprocessing. Gross margin continued to expand sequentially to reach 73.5%. We continue to build a strong foundation for future bioprocessing successes. Expanding our customer base. In this quarter, we added 37 new customers in the early phase of drug discovery, and over the past two years, we added more than 220 new customers. Our sales pipeline is strengthening, and we focus on partnering with our customers as they progress their modalities into late-stage development, which is going to be key as a leading indicator for future growth in the quarter. We took decisive actions to rightsize our bioprocessing cost base and drive strong integration, with the benefit of this starting to flow from quarter two onwards. This has been driven by a slowdown in our analytical testing activities, primarily due to a rationalization in one of our customer's operations and also some delay in purchasing decisions for systems coming mostly from the US. As a consequence of macroeconomic factors and recent announcements made by the Board. We were encouraged by the rebound in demand within the drug discovery segments, particularly in the North American area. We also saw growth in the Asia Pacific region, with China reporting quarter over quarter growth. Now, our demand continues to outstrip manufacturing capacity when it comes to our peptides. Had we been able to supply the peptide backlog, we would have been able to report mid-single digit growth in revenue for the core business. Our gross margin in the core business grew sequentially quarter over quarter and as regional, at 61.7%. Although we do recognize that the Q1 results are disappointing, we ourselves are not satisfied with them. We were pleased that March saw improvement momentum with mid-single-digit growth in consumable orders, which is very promising for onward revenue. We remain confident in our future mid to long-term outlook while managing the short-term headwinds with the right-sized cost base. Let me now turn it over to Andrew, who's going to walk you through more details on our financials. Thank you.

Andrew Kellett
03:06 - 09:22

Thank you, Fred. Good morning, everybody. The Q1 report, along with the presentation that's on the screen now, is available on the Biotage website under the investor section. And then financial reports. So in Q1, as Fred has just commented, our revenues were softer than Q1 2024, primarily due to the volatility within bioprocessing or large molecules, as we've previously flagged. Astrea has only a small number of customers who have products in the commercial stage, i.e., Released in the market. Fluctuations in demand from these customers can and do have a material impact on its revenue on a quarterly basis. Therefore, it has been repeatedly said that you cannot judge bioprocessing performance on a quarterly basis. As our business grows and matures, we see more of our early-stage customers' modalities moving into late-stage development and into production and commercialization. Our revenue concentration will ease and with it, our overall volatility. However, this is not measured in quarters, but rather in years. While we cannot say when and how fast those modalities will move through the pipeline, we are confident that the actions we are taking now will deliver the best chances of future success. Now our large molecules bioprocessing revenues were significantly down in Q1, as you've seen, due to lower plasmid preparation revenue in Q1 2025. We did not have any plasma revenue compared to approximately 90 million in Q1 2024. However, our Plasmid preparation revenue grew by 3% compared to Q1 2024. We did see growth of 3% in our small molecules revenue. Additionally, we saw growth in China of 16% in the quarter after a few years of consistent heavy declines, as we've noted in the Q1 report. We continued to see robust demand for our peptide systems, with demand outpacing manufacturing capacity, which has improved year on year. We experienced challenges in our analytical testing segment, with revenues declining by 8% year on year. This was driven by both specific macro factors and the rationalization of one of our customer's operations. We acquired 37 new customers in Q1. In early-stage research, we are adopting a much more rigorous approach to pipeline management, classifying our customers by clinical stage to give us better visibility of future revenue streams. Although we cannot predict when and if a customer will progress through the pipeline, the more customers we acquire and the more we partner with them in solving their problems, we increase our chances of future success. This, as Fred has always commented, is a numbers game requiring a medium-term outlook. While we are on this journey, we can still expect some significant short-term revenue volatility. As Fred has commented, our gross margins in the quarter were actually very strong on a group level. They were just under 63%, broadly on par with a very strong comparable Q1 2024 and up 1.1% sequentially on Q1, Q4 24. In bioprocessing, our Astrea business Q1 margins were 73.5%, up 7.87 points compared to Q1 2024 and 2.3 points sequentially. In the core quarter, one margins were 61.7%, up 5.1 points sequentially and just a small decline from a very strong comparable Q1 2024. Total operating costs in Q1 were $254 million, compared to $236 million in Q1 2024. However, when you adjust for one-off non-recurring costs, which were 22 million in Q1 versus 14 million in Q1 24, and the impact of effect translation costs, which we took an 8 million charge in Q1 versus a 5 million credit in Q1 2024. They were much higher in Q1 2025 due to significant swings in the FX rates in March, mainly centered around the US dollar. Then our adjusted OpEx at 224 million was actually lower than Q1 2024 of 227 million. So in Q1, we delivered an adjusted EBITDA of 50 million. This was weighed down by the softness in the bioprocessing revenue to mitigate this. We have taken decisive action to streamline our bioprocessing cost base and drive further integration. The benefits of this will start to flow from Q2 this year. In the quarter, we delivered adjusted cash flow from operations of 76 million, again down on the comparable quarter due to revenue softness. However, we continue to deliver adjusted cash flow from operations ahead of adjusted EBITDA. We finished the quarter with gross cash of 434 million and net cash of 182 million, on par with December 2024. To conclude, like Fredric said, we recognize that this quarter's results are disappointing, none more so than to us. However, we are very focused on putting in the building blocks for future growth. Undoubtedly, we're facing challenging headwinds, which will make 2025 quite a volatile year. But we remain confident that the actions we're executing now will put us in a good position for future success. Recognizing the executional as well as the market risks that lie ahead of us, we're now open to take any questions.

Operator
09:25 - 09:45

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Matthias Hegbloom from Handelsbanken. Please go ahead.

Unknown 1
09:48 - 10:11

Good morning. Thanks so much for taking my question. I have. First, a clarification. So, um, you stated in the report that if you had been able to deliver at the demand for Peptide Systems, it would have translated into mid-single digit growth. It's not clear to me if that was for the Biotage group or only for Biotage. If it references the group, it's a delta. Yeah, please.

Andrew Kellett
10:11 - 10:14

It's. No, it's for the core business.

Unknown 1
10:16 - 10:33

Okay. And I'm not sure I saw that in the report, but could you remind me what the organic growth for core was? So we can back out and understand the magnitude? Or if you can help me, then. In absolute terms, how large would the backlog be, which I guess is what we're trying to determine here.

Andrew Kellett
10:34 - 10:45

Well, if you think about it, we kind of consider the backlog to be just under approximately 20 million SEK for peptide systems.

Unknown 1
10:46 - 10:58

Yep. That's helpful. And, um, remind me, what alternatives do customers have when you can't deliver? And secondly, tied to that, when do you expect to be able to produce to meet demand?

Frederic Vanderhaegen
11:00 - 11:57

Yes. So yes, we are working with the third-party providers. So I think there are two impacts. First, we can't recognize revenue. Obviously. The second one is our lead time is substantial relative to the demand. So, uh, if we look into the second part, we are clearly recognizing that we're missing opportunities in the market. Uh, since customers are looking to expand their peptide purification. So, uh, our mitigation plan has been to work with our third-party providers to unleash the potential from access to the parts. That is the first step, and we are working with them to resume the output that we had last year in Q3 and Q4. But that's the maximum we can get to. So, I think we have to look for alternative paths to accelerate our market reach there, which we're exploring right now.

Unknown 1
12:00 - 12:26

That's helpful. Two more questions, please. So on slide seven with customer numbers for Astrea, it's a nice contribution to help the outside world understand the nature of your business. Unfortunately, that may be the only time we'll get to see it as well. But I wanted to understand the math here better. New customers? Is that a net number of won and lost during the year, or has that actually not lost a single customer since 2022?

Andrew Kellett
12:28 - 12:45

Um, it is a net number. But effectively, we're not losing customers. You know, the number of lost customers. I can't think of any really off the top of my head. So effectively, those are the new customers. We're winning. The level of losses is negligible.

Unknown 1
12:48 - 13:08

That's clear. And my final point is still on slide seven. Great. With the breakdown of customers per stage, but only referencing the commercial stage and more or less all columns and fiber in the preclinical stage. Can you help me understand the revenue split between reference columns and fiber? The vast majority of revenues come from reference, then. Or how should we think about that breakdown?

Andrew Kellett
13:10 - 13:38

So, in that, the majority of you can broadly think about fiber, which obviously is a new technology. The revenue from that is very small, almost negligible from an Astrea perspective. Um, and you can think of the resin column split broadly as about 85 to 90% in resins and 10 to 15% in columns.

Unknown 1
13:40 - 13:43

Very helpful. Thanks so much. Thank you.

Operator
13:51 - 14:19

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Frederic Vanderhaegen
14:20 - 15:35

So thank you. Uh, operator. So thank you to those of you who have joined this call. So we, uh, we again, want to reiterate that we are not commenting on the announcements, and we want to encourage any of you who have questions about that topic to reach out to, uh, Torben Jorgensen, who is acting as a representative of the board, or to reach out to KKR. So, as we said, we recognize that Q1 was a challenging quarter for us, mostly driven by the situation that we had in our bioprocessing space. We entered the year with a very weak backlog, but we are committed and working on expanding our customer base and addressing the opportunities, bridging the short-term revenue gap with our packing column strategies out of our Canton site that is now commissioned and operational, which will help us accelerate our momentum onwards. And in the meantime, we continue driving our drug discovery process as well as our applied market. As an organization, we have built new strategic vectors to proceed forward, and we'll be happy to share those with you as we progress onwards on the journey. Thank you all for joining us today and we look forward to speaking to you next quarter.

Fortsæt til webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Sprog: Dansk12.11.2026, 12.00
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Sprog: Engelsk12.11.2026, 10.00
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Sprog: Dansk11.11.2026, 12.00
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Sprog: Dansk5.11.2026, 08.30
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Sprog: Engelsk3.11.2026, 08.30
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Sprog: Engelsk29.10.2026, 09.30
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Sprog: Dansk22.10.2026, 08.00
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Sprog: Engelsk15.10.2026, 08.00
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Sprog: Engelsk14.10.2026, 11.00
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Sprog: Dansk28.9.2026, 09.00
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Sprog: Dansk25.8.2026, 08.00
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Sprog: Dansk21.8.2026, 12.00
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Sprog: Engelsk14.8.2026, 09.00
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Sprog: Engelsk14.8.2026, 07.30
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Sprog: Engelsk13.8.2026, 08.30
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Sprog: Engelsk12.8.2026, 07.30
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Sprog: Engelsk16.7.2026, 08.00
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Sprog: Dansk6.5.2026, 08.30
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Sprog: Engelsk6.5.2026, 07.30
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Sprog: Engelsk24.4.2026, 07.30
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…